Study shows anti-clotting drug reduced bleeding events in patients with atrial fibrillation

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial was stopped early by the recommendation of the Data Monitoring Committee due to an overwhelming reduction in bleeding compared to standard-of-care treatment.